Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum

Craig Hallum upgraded shares of Rezolute (NASDAQ:RZLT) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat reports. Craig Hallum currently has $7.00 price objective on the stock, up from their previous price objective of $4.00.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a research report on Friday, July 17th. Guggenheim boosted their target price on Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, June 15th. Citizens Jmp raised shares of Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price for the company in a report on Wednesday, June 3rd. Maxim Group raised their price target on shares of Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Rezolute in a report on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Rezolute currently has an average rating of “Moderate Buy” and a consensus target price of $10.44.

Rezolute Price Performance

Shares of RZLT opened at $4.07 on Tuesday. Rezolute has a one year low of $1.07 and a one year high of $11.46. The company has a market cap of $393.65 million, a P/E ratio of -5.36 and a beta of 0.54. The firm has a 50 day simple moving average of $4.51 and a two-hundred day simple moving average of $4.06.

Rezolute (NASDAQ:RZLT) last released its earnings results on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). On average, analysts expect that Rezolute will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

A number of hedge funds have recently made changes to their positions in the company. Jennison Associates LLC bought a new stake in shares of Rezolute during the first quarter worth about $10,489,000. Siren L.L.C. acquired a new stake in Rezolute during the 1st quarter worth approximately $10,151,000. Dimensional Fund Advisors LP boosted its position in Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock worth $1,617,000 after buying an additional 388,346 shares during the period. Knott David M Jr grew its holdings in Rezolute by 8.8% during the 1st quarter. Knott David M Jr now owns 370,000 shares of the company’s stock worth $1,128,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Rezolute during the 2nd quarter worth approximately $1,104,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.